Are you Dr. Lopatin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 39 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1233 Howard St
Apt 716
San Francisco, CA 94103Phone+1 415-935-1874- Is this information wrong?
Summary
- Dr. Uri Lopatin, MD is an infectious disease specialist in San Francisco, California. He is currently licensed to practice medicine in New York.
Education & Training
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 2003 - 2005
NYU Grossman School of MedicineResidency, Internal Medicine, 2001 - 2003
University of WashingtonInternship, Internal Medicine, 2000 - 2001
Rutgers New Jersey Medical SchoolClass of 2000
Certifications & Licensure
NY State Medical License 2002 - 2025
Publications & Presentations
PubMed
- 2 citationsEvaluation ofantiviral activity of SARS-CoV-2 Minhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.Xiao Tong, Walter Keung, Lee D Arnold, Laura J Stevens, Andrea J Pruijssers, Seunghyi Kook, Uri Lopatin, Mark Denison, Ann D Kwong> ;Antimicrobial Agents and Chemotherapy. 2023 Nov 15
- 17 citationsSafety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.Mark S Sulkowski, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Hie-Won L Hann, Douglas T Dieterich, Ronald G Nahass, James S Park, Sing Chan, Steven-Huy B ...> ;Journal of Hepatology. 2022 Nov 1
- 12 citationsSafety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Hie-Won L Hann, Douglas T Dieterich, Ronald G Nahass, James S Park, Sing Chan, Steven-Huy B Han...> ;Journal of Hepatology. 2022 Sep 1
- Join now to see all
Press Mentions
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 InfectionsAugust 26th, 2021- Pardes Biosciences Appoints Deborah M. Autor, J.D. (’92) and Laura J. Hamill to Board of DirectorsAugust 5th, 2021
Shasqi Completes $10 Million Series A FinancingOctober 31st, 2019- Join now to see all
Professional Memberships
- Member
